Entera Bio Ltd. (FRA:5DT)

Germany flag Germany · Delayed Price · Currency is EUR
2.000
+0.008 (0.40%)
At close: Nov 28, 2025
34.23%
Market Cap94.12M
Revenue (ttm)105.69K
Net Income (ttm)-9.19M
Shares Outn/a
EPS (ttm)-0.21
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume52
Open2.000
Previous Close1.992
Day's Range2.000 - 2.000
52-Week Range1.414 - 2.660
Betan/a
RSI41.45
Earnings DateMar 9, 2026

About Entera Bio

Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2009
Employees 20
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 5DT
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.